Aptevo Therapeutics Inc Total Liabilities
Aptevo Therapeutics Inc total liabilities. Based on the latest financial reports, Aptevo Therapeutics Inc (APVO) has total liabilities worth $8.48 Million USD as of June 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check APVO asset resilience ratio to evaluate the company's liquid asset resilience ratio.
Total Liabilities of Aptevo Therapeutics Inc (2014–2025)
Total liabilities of Aptevo Therapeutics Inc from 2014 to 2025. This chart illustrates how Aptevo Therapeutics Inc's total liabilities have evolved over time, based on quarterly financial data.
Aptevo Therapeutics Inc Competitors by Total Liabilities
The table below lists competitors of Aptevo Therapeutics Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
NuGen Medical Devices Inc
V:NGMD
|
Canada | CA$18.51 Million |
|
Global Power Solutions Corp.
V:PWER
|
Canada | CA$465.18K |
|
SIGNATURE RESOURCES NEW
F:3S30
|
Germany | €2.09 Million |
|
Nuwellis Inc
NASDAQ:NUWE
|
USA | $11.17 Million |
|
Lanesborough Real Estate Investment Trust
V:LRT-UN
|
Canada | CA$201.06 Million |
|
ROUTE1 INC.
F:3R6N
|
Germany | €8.59 Million |
|
Nexera Energy Inc
V:NGY
|
Canada | CA$32.63 Million |
|
Appulse Corp
V:APL
|
Canada | CA$64.25K |
Liability Composition Analysis (2014–2025)
This chart breaks down Aptevo Therapeutics Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see Aptevo Therapeutics Inc assets under control.
Liquidity & Leverage Metrics
Aptevo Therapeutics Inc Total Liabilities Ratios Explained
Aptevo Therapeutics Inc total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 2.08 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 1.40 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.58 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Aptevo Therapeutics Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Aptevo Therapeutics Inc (2014–2025)
The table below shows the annual total liabilities of Aptevo Therapeutics Inc from 2014 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $9.81 Million | -9.44% |
| 2024-12-31 | $10.84 Million | -14.14% |
| 2023-12-31 | $12.62 Million | -22.29% |
| 2022-12-31 | $16.24 Million | -70.68% |
| 2021-12-31 | $55.38 Million | +49.88% |
| 2020-12-31 | $36.95 Million | -11.10% |
| 2019-12-31 | $41.57 Million | +12.07% |
| 2018-12-31 | $37.09 Million | +6.05% |
| 2017-12-31 | $34.97 Million | -15.31% |
| 2016-12-31 | $41.29 Million | +73.22% |
| 2015-12-31 | $23.84 Million | -6.01% |
| 2014-12-31 | $25.36 Million | -- |
About Aptevo Therapeutics Inc
Aptevo Therapeutics Inc., a clinical-stage research and development biotechnology company, focuses on developing immunotherapeutic candidates for the treatment of various forms of cancer in the United States. The company develops its products using ADAPTIR and ADAPTIR-FLEX platforms to generate monospecific, bispecific, and multi-specific antibody candidates capable of enhancing the human immune … Read more